Chemistry:2-Oxo-3-hydroxy-LSD

From HandWiki

2-Oxo-3-hydroxy-LSD, or 2-oxy-3-hydroxy-LSD, also known as O-H-LSD or OH-LSD, as well as more fully as 2-oxo-3-hydroxy-2,3-dihydro-LSD, is a lysergamide and the major metabolite of the psychedelic drug lysergic acid diethylamide (LSD).[1][2][3][4][5] LSD is eliminated 13% as O-H-LSD in urine within 24 hours[6] and urinary concentrations of O-H-LSD are 4 to 40 times those of LSD in humans.[7][3][8][9]

The specific enzymes responsible for the formation of O-H-LSD from LSD are unclear.[6][8][9][3] However, subsequent research found involvement of several cytochrome P450 enzymes.[10] O-H-LSD is thought to form from other LSD metabolites like 2-oxo-LSD and 3-hydroxy-LSD.[7][3][8][9][11]

It is unknown whether O-H-LSD is pharmacologically active or produces hallucinogenic effects.[6][5] However, O-H-LSD showed profoundly reduced albeit still detectable activity at the serotonin 5-HT2 receptors, including the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, compared to LSD in vitro.[10]

O-H-LSD was first described in the scientific literature by at least the 1990s.[12][13] It started being sold online as an analytical standard by 2024.[5]

See also

References

  1. "Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)". ACS Chemical Neuroscience 9 (10): 2331–2343. October 2018. doi:10.1021/acschemneuro.8b00043. PMID 29461039. https://shaunlacob.com/wp-content/uploads/2020/12/DC-LSD.pdf. 
  2. "The pharmacology of lysergic acid diethylamide: a review". CNS Neuroscience & Therapeutics 14 (4): 295–314. 2008. doi:10.1111/j.1755-5949.2008.00059.x. PMID 19040555. 
  3. 3.0 3.1 3.2 3.3 "Indolealkylamines: biotransformations and potential drug-drug interactions". The AAPS Journal 10 (2): 242–253. June 2008. doi:10.1208/s12248-008-9028-5. PMID 18454322. 
  4. Dolder P (2017). The Pharmacology of d-Lysergic Acid Diethylamide (LSD) (PDF) (Thesis). University of Basel. doi:10.5451/UNIBAS-006786123.
  5. 5.0 5.1 5.2 "3-Гидрокси-2-оксо-ЛСД (2-oxo-3-hydroxy-LSD)" (in ru). 10 November 2015. https://aipsin.com/newsubstance/1551/. 
  6. 6.0 6.1 6.2 "Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans". The International Journal of Neuropsychopharmacology 19 (1). June 2015. doi:10.1093/ijnp/pyv072. PMID 26108222. "In the present study, 13% of the orally administered LSD was recovered from urine as O-H-LSD within 24 hours. LSD is metabolized to O-H-LSD by cytochrome P450 enzymes, but the specific enzymes and mechanisms are unknown (Klette et al., 2000). To our knowledge, it is unknown whether O-H-LSD is pharmacologically active.". 
  7. 7.0 7.1 The Pharmacology of LSD. OUP/Beckley Foundation Press. 10 June 2010. p. 29. ISBN 978-0-19-958982-1. https://books.google.com/books?id=KTyC-e7NmI8C&pg=PA29. "Fig. 2.7 Metabolites of LSD. [...]" 
  8. 8.0 8.1 8.2 "Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse". Pharmacogenomics 12 (2): 215–233. February 2011. doi:10.2217/pgs.10.171. PMID 21332315. "It is rapidly metabolized to the following five metabolites which have been identified in urine or blood from human users: N-demethyl-LSD (nor-LSD), 2-oxo-LSD, 2-oxo-3-hydroxy-LSD, 13-hydroxyLSD and 14-hydroxy-LSD [187–189]. The 13- and 14-hydroxy metabolites are additionally excreted as glucuronides [188]. However, 2-oxo-LSD may be an intermediate in the formation of 2-oxo-3-hydroxy-LSD. Following the incubation of LSD with HLM and hepatocytes, 2,3-dihydroxy-LSD could be identified [190]. 2-oxo-3-hydroxy-LSD was shown to be the main human urinary metabolite with concentrations four- to 40-times higher than that of LSD [187,188,191]. As concluded by Yu in his review on indolalkylamines, almost nothing is known regarding the contribution of specific drug-metabolizing enzymes to the production of individual LSD metabolites in humans.". 
  9. 9.0 9.1 9.2 "Drugs of Abuse (Including Designer Drugs)". Metabolism of Drugs and Other Xenobiotics. Wiley. 18 April 2012. pp. 429–463. doi:10.1002/9783527630905.ch16. ISBN 978-3-527-32903-8. "It is metabolized to the following five metabolites: N-demethyl-LSD (nor-LSD), 2-oxo-LSD, 2-oxo-3-hydroxy-LSD, 13-hydroxy-LSD, and 14-hydroxy-LSD [72–74]. The 13- and 14-hydroxy metabolites are additionally excreted as glucuronides [74]. 2-Oxo-3-hydroxy-LSD was shown to be the main human urinary metabolite with concentrations 4–40 times higher than that of LSD [73–75]. In incubations of LSD with human liver microsomes and hepatocytes, 2,3-dihydroxy-LSD could be identified [71]. So far, the contribution and importance of specific enzymes in the formation of the LSD main metabolites such as 2-oxo-3-hydroxy-LSD still remains unclear." 
  10. 10.0 10.1 "Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use". Biochemical Pharmacology 164: 129–138. June 2019. doi:10.1016/j.bcp.2019.04.013. PMID 30981875. 
  11. "Metabolism of lysergic acid diethylamide (LSD): an update". Drug Metabolism Reviews 51 (3): 378–387. August 2019. doi:10.1080/03602532.2019.1638931. PMID 31266388. "In vitro studies using liver microsomes and human cryopreserved hepatocytes showed that O-HLSD is a product of LSD biotransformation whose amount increases in a time-dependent manner. In the same study was detected another metabolite in a time-dependent manner upon incubation, the dihydroxy-LSD (Klette et al. 2000). Therefore, LSD is oxidized to 2-oxo-LSD, which undergoes subsequent hydroxylation to O-H-LSD. Although the formation of O-H-LSD may occur via intermediate metabolite dihydroxy-LSD (Figure 1) (Klette et al. 2002).". 
  12. "Détection de l'acide lysergique diéthylamide (LSD) dans l'urine humaine: élimination, dépistage et confirmation analytique" (in French). Schweizerische Medizinische Wochenschrift 121 (50): 1887–1890. December 1991. PMID 1759150. 
  13. "New synthesis and characterization of (+)-lysergic acid diethylamide (LSD) derivatives and the development of a microparticle-based immunoassay for the detection of LSD and its metabolites". Bioconjugate Chemistry 8 (6): 896–905. 1997. doi:10.1021/bc9700594. PMID 9404664.